PE
Live price temporarily unavailable.
Price history
Penumbra (PEN) is a Health Care company in the Russell 1000. Latest news and coverage below.
IPO: September 18, 2015 · $30.00 offering · New York Stock Exchange · View IPO details →
Penumbra revenue & net income history (FY2016–FY2025)
RevenueNet income
| FY2016Dec 2016 | FY2017Dec 2017 | FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $263.3M | $333.8M | $444.9M | $547.4M | $560.4M | $747.6M | $847.1M | $1.06B | $1.19B | $1.40B |
| Growth (year over year) | +41.5% | +26.8% | +33.3% | +23.0% | +2.4% | +33.4% | +13.3% | +25.0% | +12.9% | +17.5% |
| Gross profit | $170.8M | $217.1M | $292.5M | $372.0M | $338.2M | $475.4M | $535.2M | $682.6M | $755.0M | $942.4M |
| Gross margin | 64.9% | 65.1% | 65.7% | 68.0% | 60.3% | 63.6% | 63.2% | 64.5% | 63.2% | 67.1% |
| Operating income | −$1.35M | $1.17M | −$852.0K | $47.5M | −$38.9M | −$7.50M | $6.08M | $73.6M | $9.28M | $189.2M |
| Operating margin | −0.5% | 0.3% | −0.2% | 8.7% | −6.9% | −1.0% | 0.7% | 6.9% | 0.8% | 13.5% |
| Net income | $14.8M | $4.66M | $6.60M | $48.5M | −$15.7M | $5.28M | −$2.00M | $91.0M | $14.0M | $177.7M |
| Net margin | 5.6% | 1.4% | 1.5% | 8.9% | −2.8% | 0.7% | −0.2% | 8.6% | 1.2% | 12.7% |
| EPS (diluted) | $0.44 | $0.13 | $0.18 | $1.34 | −$0.44 | $0.14 | −$0.05 | $2.32 | $0.36 | $4.52 |
| Balance sheet | ||||||||||
| Cash and equivalents | $13.2M | $50.6M | $67.8M | $72.8M | $69.7M | $59.4M | $69.9M | $167.5M | $324.4M | $186.9M |
| Total assets | $308.3M | $476.7M | $557.9M | $665.9M | $823.0M | $1.24B | $1.37B | $1.56B | $1.53B | $1.83B |
| Total liabilities | $41.7M | $76.3M | $135.4M | $180.3M | $185.2M | $290.3M | $372.0M | $377.4M | $382.3M | $398.9M |
| Shareholders' equity | $266.5M | $400.4M | $422.2M | $485.9M | $641.5M | $953.9M | $998.9M | $1.18B | $1.15B | $1.43B |
| Cash flow | ||||||||||
| Operating cash flow | −$12.8M | $12.7M | $28.8M | $26.7M | −$33.2M | $9.50M | −$55.7M | $97.3M | $168.5M | $238.7M |
| Capital expenditure | $13.6M | $12.5M | $9.60M | $22.1M | $24.8M | $21.2M | $19.3M | $15.2M | $21.2M | $63.7M |
| Free cash flow | −$26.4M | $159.0K | $19.2M | $4.54M | −$58.0M | −$11.7M | −$75.0M | $82.1M | $147.3M | $174.9M |
| Share buybacks | — | — | — | — | — | — | $0 | $0 | $100.4M | $0 |
RevenueNet income
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $301.0M | $315.5M | $324.1M | $339.5M | $354.7M | $385.4M | $374.8M | $390.0M |
| Growth (year over year) | +11.1% | +10.8% | +16.3% | +13.4% | +17.8% | +22.1% | +15.6% | +14.9% |
| Gross profit | $200.3M | $210.7M | $215.9M | $224.0M | $240.4M | $262.1M | $253.4M | $264.9M |
| Gross margin | 66.5% | 66.8% | 66.6% | 66.0% | 67.8% | 68.0% | 67.6% | 67.9% |
| Operating income | $35.4M | $42.8M | $40.4M | $40.8M | $48.8M | $59.2M | $38.2M | $41.0M |
| Operating margin | 11.7% | 13.6% | 12.4% | 12.0% | 13.8% | 15.4% | 10.2% | 10.5% |
| Net income | $29.5M | $33.7M | $39.2M | $45.3M | $45.9M | $47.3M | $32.6M | $34.8M |
| Net margin | 9.8% | 10.7% | 12.1% | 13.3% | 12.9% | 12.3% | 8.7% | 8.9% |
| EPS (diluted) | $0.75 | $0.88 | $1.00 | $1.15 | $1.17 | $1.20 | $0.82 | $0.88 |
| Balance sheet | ||||||||
| Cash and equivalents | $280.5M | $324.4M | $376.1M | $421.8M | $321.0M | $186.9M | $241.3M | $205.3M |
| Total assets | $1.48B | $1.53B | $1.59B | $1.67B | $1.74B | $1.83B | $1.90B | $1.97B |
| Total liabilities | $374.8M | $382.3M | $380.4M | $380.9M | $385.7M | $398.9M | $424.6M | $444.0M |
| Shareholders' equity | $1.10B | $1.15B | $1.21B | $1.29B | $1.36B | $1.43B | $1.47B | $1.53B |
| Cash flow | ||||||||
| Operating cash flow | $56.5M | $51.1M | $49.0M | $44.9M | $58.3M | $86.5M | $87.0M | $46.1M |
| Capital expenditure | $5.45M | $5.37M | $13.5M | $15.6M | $16.2M | $18.4M | $13.7M | $13.5M |
| Free cash flow | $51.0M | $45.7M | $35.5M | $29.4M | $42.0M | $68.0M | $73.3M | $32.5M |
| Share buybacks | — | −$1.00K | — | — | — | $0 | — | — |
From Penumbra's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
About Penumbra
- Headquarters
- Alameda, California From SEC filings, Oct 2026
Recent News (1)
More Health Care stocks
- ILMN Illumina
- A Agilent Technologies
- ABBV AbbVie
- ABT Abbott Laboratories
- ALGN Align Technology
- ALNY Alnylam Pharmaceuticals
- AMGN Amgen
- BAX Baxter International